Krystal Biotech (KRYS) Long-Term Deferred Tax (2025 - 2026)
Krystal Biotech (KRYS) posted quarterly Long-Term Deferred Tax of $22.8 million for Q2 2026, little changed on a QoQ basis from $22.8 million in Q1 2026.
Krystal Biotech (KRYS) Long-Term Deferred Tax (2025 - 2026) Analysis & Trends
Krystal Biotech has reported Long-Term Deferred Tax for 2 years, with the latest figure at $22.8 million in Q2 2026.
- Long-Term Deferred Tax for Q2 2026 came in at $22.8 million, changed N/A year-over-year; the trailing twelve-month figure through Jun 2026 was $22.8 million (changed N/A YoY), and the FY2025 annual result was $22.8 million, changed N/A from the prior year.
- Long-Term Deferred Tax held at $22.8 million in Q2 2026, from $22.8 million in the prior quarter.
- Over five years, Long-Term Deferred Tax peaked at $24.7 million in Q3 2025 and troughed at $22.8 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Krystal Biotech | 9.83 Bn | 8.99 Bn | 112.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 22.82 Mn |
| Mar 31, 2026 | 22.82 Mn |
| Dec 31, 2025 | 22.82 Mn |
| Sep 30, 2025 | 24.68 Mn |